Orion Biotech Opportunities Corp. Warrant
ORIAW
ORIAW was delisted on the 28th of April, 2023.
29 hedge funds and large institutions have $2.14M invested in Orion Biotech Opportunities Corp. Warrant in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.
3% less funds holding
Funds holding: 30 → 29 (-1)
18% less capital invested
Capital invested by funds: $2.63M → $2.14M (-$482K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$8.29K |
| 2 |
CS
Clear Street
New York
|
+$1.84K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
-$10K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$710 |
| 3 |
CCM
Context Capital Management
Lajolla,
California
|
-$278 |
| 4 |
EAM
Empery Asset Management
New York
|
-$97 |
ORIAW Hedge Fund Activity: Q2 2022 in Review
29 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Orion Biotech Opportunities Corp. Warrant (ORIAW) for Q2 2022, worth a combined $2.14M — down 18% from $2.63M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ORIAW and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 2 added.
The largest buyer was Shaolin Capital Management, adding an estimated $8.29K. The largest seller was Cowen and Company, exiting entirely with an estimated $10K sold.
- 29 institutional investors held Orion Biotech Opportunities Corp. Warrant (ORIAW) as of Q2 2022, down from 30 in Q1 2022.
- Funds reported $2.14M of Orion Biotech Opportunities Corp. Warrant stock for Q2 2022, down 18% quarter-over-quarter.
- 2 funds opened new Orion Biotech Opportunities Corp. Warrant positions in Q2 2022 and 3 closed out, a net change of -1 holder.
- The largest Orion Biotech Opportunities Corp. Warrant buyer in Q2 2022 was Shaolin Capital Management, an estimated $8.29K added.
- The largest Orion Biotech Opportunities Corp. Warrant seller in Q2 2022 was Cowen and Company, an estimated $10K sold.
Based on aggregated 13F filings for Q2 2022.